Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 6/20 | 0.39 |
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | CA3 | P07451 | 2/20 | 0.35 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31689531 | 1.00 | LMNA (0.41) | LMNATDP1CA2CA1CA9 | |
| SCHEMBL30454637 | 0.83 | LMNA (0.47) | LMNATDP1CA2CA1CA9 | |
| SCHEMBL17985 | 0.83 | LMNA (0.47) | LMNATDP1CA2CA1CA9 | |
| SCHEMBL6782609 | 0.83 | ALDH1A1 (0.48) | LMNATDP1CA2CA1CA9 | |
| SCHEMBL30098266 | 0.81 | PTGS2 (0.42) | LMNATDP1CA2CA1CA9 | |
| SCHEMBL1368195 | 0.81 | CA2 (0.61) | LMNACA2CA1CA9CA12 | |
| SCHEMBL31402607 | 0.81 | LMNA (0.42) | LMNATDP1CA2CA1CA9 | |
| SCHEMBL2586501 | 0.81 | PTGS2 (0.42) | LMNATDP1CA2CA1CA9 | |
| SCHEMBL3194901 | 0.80 | CA2 (0.43) | TDP1CA2CA1CA9CA12 | |
| SCHEMBL994541 | 0.80 | TDP1 (0.61) | LMNATDP1ALDH1A1HSD17B10TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | disclosed |
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| EP-4561994-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | Genecode (EE) | 2025-06-04 | — | — | EP | disclosed |
| CN-119948015-A | Novel sulfonamides and their use as neuroprotective and/or nerve repair agents | 基因密码公司 | 2025-05-06 | — | — | CN | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024023284-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2024-02-01 | — | — | WO | disclosed |
| US-20220251087-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2022-08-11 | — | — | US | disclosed |
| US-11306079-B2 | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors | INCYTE CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| US-8722656-B2 | Cephalosporins useful as antibacterial agents | ZOETIS LLC (US) | 2014-05-13 | — | — | US | disclosed |
| CN-103649097-A | Novel cephalosporins used as antibacterial agents | ZOETIS LLC | 2014-03-19 | — | — | CN | disclosed |
| EP-2705044-A1 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS | ZOETIS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| WO-2012150520-A1 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| US-20120283237-A1 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2012-11-08 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-6388083-B2 | ANTAGONIST TO SUBSTANCE P RECEPTORS | MERCK & CO., INC. | 2002-05-14 | — | — | US | disclosed |
| US-20020019532-A1 | Process for the synthesis of (2S)-phenyl-3-piperidone | MERCK & CO., INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | LMNA 4750/4885TDP1 1176/4885CA2 3741/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | LMNA 4311/4885TDP1 601/4885CA2 2281/4885 |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | LMNA 1359/4885TDP1 2804/4885CA2 240/4885 |
| US-11306079-B2 | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors | PIK3CG, PIK3CD, PIK3CA | LMNA 3037/4885TDP1 700/4885CA2 2884/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | LMNA 4750/4885TDP1 1176/4885CA2 3741/4885 |
| US-20020019532-A1 | Process for the synthesis of (2S)-phenyl-3-piperidone | DHPS, NPEPPS, ALDH18A1 | LMNA 3683/4885TDP1 4500/4885CA2 4158/4885 |
| US-20120283237-A1 | NOVEL CEPHALOSPORINS USEFUL AS ANTIBACTERIAL AGENTS | CIAPIN1, CLSPN, MRPL21 | LMNA 3599/4885TDP1 4190/4885CA2 3749/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | LMNA 4750/4885TDP1 1176/4885CA2 3741/4885 |
| US-20220251087-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | LMNA 3480/4885TDP1 370/4885CA2 2677/4885 |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, MMP3, TIMP3 | LMNA 2524/4885TDP1 2054/4885CA2 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.